Q4 2022
Released Mar 8, 2023, after the close
10-K filed Mar 23, 2023, 82 days after period end · 0001493152-23-008716
Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$2.56M$2.56M derived−3.0% vs Q4 2021+6.1% vs Q3 2022
Net Income-$771.00K-$771.00K derivedN/M vs Q4 2021N/M vs Q3 2022
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived$1,521,000+7.8%
Operating Incomederived-$693,000N/M
Operating Cash Flowderived-$195,000N/M
Free Cash Flowderived-$195,000N/M
Margins · derived
Gross margin59.5%+6.0 pt vs Q4 2021
Operating margin-27.1%−15.2 pt vs Q4 2021
Net margin-30.2%+7.1 pt vs Q4 2021
What the release said
The release
Same quarter
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019dderived from reported figures |
|---|---|---|---|---|
| Revenue | $2.56M | $2.64M | $2.33M | $3.16M |
| Net Income | -$771.00K | -$982.00K | -$759.00K | -$144.00K |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nephros Inc · CIK 1196298 · Engraved from SEC EDGAR